Ticker: ALT

Altimmune, Inc. (ALT) - quick read: late clinical‑stage biotech; pemvidutide Phase 2b (IMPACT) reported strong topline efficacy; company materially strengthened cash position in H1 2025 via equity raises and a term loan, but still reports no product revenue and substantial ongoing losses. All dol...

Altimmune, Inc. (NASDAQ: ALT) has recently published its quarterly report for the period ending March 31, 2025, showcasing significant developments in its operations and financial performance. Key Financial Highlights: Revenues: Consistent at $5, unchanged from the prior year. Operating Expenses...